Gossamer Bio, Inc. (GOSS) Stock
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc. is led by CEO Faheem Hasnain, employs 144 people, headquartered in US, publicly traded since 2019.
Gossamer Bio, Inc. (GOSS) stock trades at $9.61 with a market capitalization of $58.69M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.20, reflecting a net loss over the last twelve months, a negative price-to-book of -0.26, reflecting negative shareholders' equity, price-to-sales of 1.02. Over the past 52 weeks the stock has ranged between $8.29 and $309.60, and currently trades 96.9% below its 52-week high.
On profitability, Gossamer Bio, Inc. generates a return on equity (ROE) of 108.75% (not meaningful, as shareholders' equity is negative), return on capital employed of 272.66%, an operating margin of -339.58%, a net profit margin of -235.00%.
Official website: www.gossamerbio.com
Gossamer Bio, Inc. by the numbers, 2016–2025
Between 2016 and 2025 Gossamer Bio, Inc. reported revenue of $0 rising to $48.0M. Compounded, revenue has grown —% a year over five years, —% over three, -58.3% over the last twelve months. Net profit was $-170.0M in 2025.
The most recent net margin is -235.00%. On a trailing twelve-month basis to Jun '26, revenue is $53.0M and net profit $-125.0M.
Borrowings stand at $203.0M, cash from operations was $-171.0M in the latest year, positive in 0 of the last 10.
Return on equity has averaged -489.1% over five years, and was 138.2% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Gossamer Bio, Inc. (GOSS) — frequently asked questions
What is Gossamer Bio, Inc. (GOSS) stock price today?
Gossamer Bio, Inc. (GOSS) is currently trading at $9.61, up 1.53% today.
What is GOSS P/E ratio?
Gossamer Bio, Inc.'s P/E ratio is -0.20. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is GOSS return on equity (ROE)?
Gossamer Bio, Inc.'s return on equity (ROE) is 108.75%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.
What is Gossamer Bio, Inc.'s market cap?
Gossamer Bio, Inc. has a market capitalization of $58.69M.
Does GOSS pay a dividend?
Gossamer Bio, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does GOSS carry?
Gossamer Bio, Inc. has a debt-to-equity ratio of -0.42. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is GOSS's profit margin?
Gossamer Bio, Inc. reports a net profit margin of -235.00% — the share of revenue left after every cost, including tax and interest.
What sector is GOSS in?
Gossamer Bio, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is GOSS listed on?
Gossamer Bio, Inc. trades on NASDAQ under the ticker GOSS.
What is GOSS's 52-week range?
Over the last year Gossamer Bio, Inc. has traded between $8.29 and $309.60.
Related Healthcare Stocks
Popular Stocks
Screens GOSS currently matches
On the figures above, Gossamer Bio, Inc. passes the filters for 1 of our ready-made screens, among them Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.